Related Experiment Video
Updated: Mar 3, 2026

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational
Luca Moscetti1,2, Lucia Mentuccia3, Patrizia Vici4
1Division of Medical Oncology, AUSL Viterbo, Belcolle Hospital, Viterbo, Italy.
Aim:
Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations.
Patients & Methods:
A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires.
Results:
A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores.
Conclusion:
The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
06:03Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
Published on: February 6, 2020